Budesonide Suspension for Inhalation Shortage

• • Budesonide inhalation suspension, Amneal, 0.25 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 00115-1687-74 - discontinued
  • Budesonide inhalation suspension, Amneal, 0.5 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 00115-1689-74 - discontinued
  • Budesonide inhalation suspension, Cipla USA, 0.25 mg / 2 mL, single-dose ampules in individual pouches, 30 count, NDC 69097-0318-53
  • Budesonide inhalation suspension, Cipla USA, 0.25 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 69097-0318-87
  • Budesonide inhalation suspension, Lupin, 0.5 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 68180-0984-30
  • Budesonide inhalation suspension, Nephron Pharmaceuticals Corporation, 0.5 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 00487-9701-01
  • Budesonide inhalation suspension, Nephron Pharmaceuticals Corporation, 0.5 mg / 2 mL, single-dose ampules in individual pouches, 30 count, NDC 00487-9701-30
  • Budesonide inhalation suspension, Teva, 0.25 mg / 2 mL, single-dose ampules in individual pouches, 30 count, NDC 00093-6815-55
  • Budesonide inhalation suspension, Teva, 0.25 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 00093-6815-73
  • Budesonide inhalation suspension, Teva, 0.5 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 00093-6816-73
  • Budesonide inhalation suspension, Teva, 0.5 mg / 2 mL, single-dose ampules in individual pouches, 30 count, NDC 00093-6816-55
  • Budesonide inhalation suspension, Teva, 1 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 00093-6817-73

• • Amneal has discontinued budesonide inhalation suspension.
  • AstraZeneca states Pulmicort Respules are available.
  • Cipla did not provide a reason for the shortage.
  • Lupin did not provide a reason for the shortage.
  • Nephron is prioritizing the production of albuterol inhalation solution.
  • Sandoz did not provide a reason for the shortage.
  • Teva did not provide a reason for the shortage.

• • Budesonide inhalation suspension, Cipla USA, 0.5 mg / 2 mL, single-dose ampules in individual pouches, 30 count, NDC 69097-0319-53
  • Budesonide inhalation suspension, Cipla USA, 0.5 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 69097-0319-87
  • Budesonide inhalation suspension, Cipla USA, 1 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 69097-0321-87
  • Budesonide inhalation suspension, Cipla USA, 1 mg / 2 mL, single-dose ampules in individual pouches, 30 count, NDC 69097-0321-53
  • Budesonide inhalation suspension, Nephron Pharmaceuticals Corporation, 0.25 mg / 2 mL, single-dose ampules in individual pouches, 30 count, NDC 00487-9601-30
  • Budesonide inhalation suspension, Nephron Pharmaceuticals Corporation, 0.25 mg / 2 mL, 5 single-dose ampules per pouch, 6 pouches, 30 count, NDC 00487-9601-01

Estimated Resupply Dates

• • Cipla has budesonide 0.25 mg/2 mL (individually packaged) on back order and the company cannot estimate a release date. The 0.25 mg/2 mL (5 vials per pouch) presentations are available with short expiration dating.
  • Lupin has budesonide 0.5 mg/2 mL (5 vials per pouch) inhalation suspension on allocation.
  • Nephron has budesonide 0.5 mg/2 mL inhalation suspension on intermittent back order and the company is releasing supplies as they become available.
  • Sandoz has all budesonide inhalation suspension presentations temporarily unavailable.
  • Teva has budesonide inhalation 0.25 mg/2 mL vials (individually packaged) and 0.5 mg/2 mL (5 vials per pouch) on back order and the company cannot estimate a release date. The 0.25 mg/2 mL (5 vials per pouch) are on intermittent back order and the company is releasing supplies as they become available. The 0.5 mg/2 mL (individually packaged) and 1 mg/2mL (5 vials per pouch) are on back order and the company estimates a release date of mid- to late-June 2024 for the 0.5 mg/2 mL and late-June 2024 for the 1 mg/2mL presentation.